基于肠道菌群从脾胃论治桥本甲状腺的研究概述
Overview of a Study on the Treatment of Hashimoto’s Thyroid from the Perspective of the Spleen-Stomach Theory Based on Intestinal Flora
DOI: 10.12677/tcm.2025.144233, PDF,   
作者: 王佳琪:黑龙江中医药大学研究生院,黑龙江 哈尔滨;郅扶旻*:黑龙江中医药大学附属第一医院内分泌科,黑龙江 哈尔滨
关键词: 肠道菌群脾胃桥本甲状腺炎“瘿病”研究概述Intestinal Flora Spleen and Stomach Hashimoto’s Thyroiditis “Gall Disease” Research Overview
摘要: 在中医理论中,桥本甲状腺炎通常被归入“瘿病”、“瘿气”以及“瘿瘤”等范畴之内。作为一种自身免疫性疾病,该病在临床上相对常见,其病程特点是持续时间较长且进展较为缓慢。若未能采取及时且有效的治疗措施,可能会对患者的健康状况造成诸多不利影响。鉴于肠道菌群在疾病演变过程中的重要性日益凸显,并考虑到脾胃作为人体后天发育之根本的生理特征,当前临床研究正兴起一种新趋势,即从脾胃的视角出发,深入探讨相关疾病的病因病理机制,并据此指导治疗策略的制定。文章聚焦于肠道菌群视角,融合理论剖析与临床实践经验,旨在探索运用脾胃调理策略治疗桥本甲状腺炎的有效途径。其主要目标是减轻患者的临床症状,同时维持肠道微生态的平衡,以期为桥本甲状腺疾病的临床预防和治疗提供新的理论视角和实践指导。
Abstract: In Chinese medicine, Hashimoto’s thyroiditis is often categorized as “gall disease,” “gall gas,” and “gall tumor.” As an autoimmune disease, it is relatively common in clinical practice, and its course is characterized by a long duration and slow progression. Failure to take timely and effective therapeutic measures may have many adverse effects on the patient’s health. In view of the increasing importance of intestinal flora in the evolution of diseases, and taking into account the physiological characteristics of the spleen and stomach as the foundation of the human body’s innate development, a new trend in clinical research is emerging, which is to explore the etiological and pathological mechanisms of related diseases from the perspective of the spleen and stomach and to guide the formulation of therapeutic strategies accordingly. This article focuses on the perspective of intestinal flora, integrates theoretical analysis and clinical practice experience, and aims to explore the effective way of treating Hashimoto’s thyroiditis by using spleen and stomach regulating strategies. The main goal is to reduce the clinical symptoms of patients and maintain the balance of intestinal microecology, in order to provide new theoretical perspectives and practical guidance for the clinical prevention and treatment of Hashimoto’s thyroid disease.
文章引用:王佳琪, 郅扶旻. 基于肠道菌群从脾胃论治桥本甲状腺的研究概述[J]. 中医学, 2025, 14(4): 1550-1558. https://doi.org/10.12677/tcm.2025.144233

参考文献

[1] 向光大. 临床甲状腺病学[M]. 北京: 人民卫生出版社, 2013.
[2] 郑慧娟, 魏璠, 柏力萄, 等. 基于中医传承辅助系统治疗桥本甲状腺炎的组方规律[J]. 世界中医药, 2018, 13(9): 2346-2351.
[3] 李军, 王丹, 薛耀明. 中药联合西药对桥本氏甲状腺炎自身抗体的影响: 随机对照临床研究的系统评价[J]. 国际医药卫生导报, 2015(15): 2115-2120.
[4] Ragusa, F., Fallahi, P., Elia, G., Gonnella, D., Paparo, S.R., Giusti, C., et al. (2019) Hashimotos’ Thyroiditis: Epidemiology, Pathogenesis, Clinic and Therapy. Best Practice & Research Clinical Endocrinology & Metabolism, 33, Article ID: 101367. [Google Scholar] [CrossRef] [PubMed]
[5] 张凌宇, 张梦云, 李净, 等. 新安医家对李杲脾胃学说的发挥[J]. 环球中医药, 2024, 17(5): 831-834.
[6] 程建林, 翁畅, 孙可昕, 等. 试述《脾胃论》中以脾胃为核心的五脏观[J]. 新中医, 2024, 56(16): 32-36.
[7] 刘翔, 朱建敏. 浅谈脾胃学说在桥本甲状腺炎治疗中的应用[J]. 中国中医药现代远程教育, 2022, 20(10): 132-133.
[8] 徐首静, 祁烁, 商建伟, 等. 甲状腺功能正常的桥本甲状腺炎患者临床症状及证型分布规律[J]. 中国医药导报, 2022, 19(29): 134-138.
[9] Thursby, E. and Juge, N. (2017) Introduction to the Human Gut Microbiota. Biochemical Journal, 474, 1823-1836. [Google Scholar] [CrossRef] [PubMed]
[10] Rinninella, E., Raoul, P., Cintoni, M., Franceschi, F., Miggiano, G.A.D., Gasbarrini, A., et al. (2019) What Is the Healthy Gut Microbiota Composition? A Changing Ecosystem across Age, Environment, Diet, and Diseases. Microorganisms, 7, Article No. 14. [Google Scholar] [CrossRef] [PubMed]
[11] 阚宝芹, 王晓武, 马志军, 等. 肠道菌群与桥本甲状腺炎关系的研究进展[J]. 医学综述, 2022, 28(4): 649-653.
[12] 罗成, 叶远航, 郑岚, 等. 中医药基于“肺-肠”轴调节肠道菌群治疗重症肺炎机制的研究进展[J]. 中国医药导报, 2023, 20(6): 33-36.
[13] 罗成, 叶远航, 盛国光, 等. 宣白承气汤及其加减方治疗呼吸系统疾病研究进展[J]. 中成药, 2023, 45(10): 3369-3375.
[14] Park, E.M., Chelvanambi, M., Bhutiani, N., Kroemer, G., Zitvogel, L. and Wargo, J.A. (2022) Targeting the Gut and Tumor Microbiota in Cancer. Nature Medicine, 28, 690-703. [Google Scholar] [CrossRef] [PubMed]
[15] Shah, S.C. and Itzkowitz, S.H. (2022) Colorectal Cancer in Inflammatory Bowel Disease: Mechanisms and Management. Gastroenterology, 162, 715-730.e3. [Google Scholar] [CrossRef] [PubMed]
[16] Chen, Z., He, S., Wei, Y., Liu, Y., Xu, Q., Lin, X., et al. (2023) Fecal and Serum Metabolomic Signatures and Gut Microbiota Characteristics of Allergic Rhinitis Mice Model. Frontiers in Cellular and Infection Microbiology, 13, Article ID: 1150043. [Google Scholar] [CrossRef] [PubMed]
[17] 李美凤, 沈睿, 董伟, 等. 胃癌脾胃虚弱证的肠道标志菌群分析[J]. 中华中医药学刊, 2021, 39(4): 138-142.
[18] Bidell, M.R., Hobbs, A.L.V. and Lodise, T.P. (2022) Gut Microbiome Health and Dysbiosis: A Clinical Primer. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 42, 849-857. [Google Scholar] [CrossRef] [PubMed]
[19] 赵微微, 张立德. 从肠道菌群与“脾胃学说”的关系探究针灸治疗高血压的可行性[J]. 实用中医内科杂志, 2019, 33(7): 77-79.
[20] 温永天, 王凤云, 唐旭东, 等. 从肠道菌群探讨“内伤脾胃, 百病由生”的科学内涵[J]. 中华中医药杂志, 2022, 37(8): 4334-4337.
[21] Zhao, F., Feng, J., Li, J., Zhao, L., Liu, Y., Chen, H., et al. (2018) Alterations of the Gut Microbiota in Hashimoto’s Thyroiditis Patients. Thyroid, 28, 175-186. [Google Scholar] [CrossRef] [PubMed]
[22] Gong, B., Wang, C., Meng, F., et al. (2021) Association between Gut Microbiota and Autoimmune Thyroid Disease: A Systematic Review and Meta-Analysis. Frontiers in Endocrinology, 36, 586-597.
[23] Pyzik, A., Grywalska, E., Matyjaszek-Matuszek, B. and Roliński, J. (2015) Immune Disorders in Hashimoto’s Thyroiditis: What Do We Know So Far? Journal of Immunology Research, 2015, Article ID: 979167. [Google Scholar] [CrossRef] [PubMed]
[24] Kudva, A.K., Shay, A.E. and Prabhu, K.S. (2015) Selenium and Inflammatory Bowel Disease. American Journal of Physiology-Gastrointestinal and Liver Physiology, 309, G71-G77. [Google Scholar] [CrossRef] [PubMed]
[25] Liu, S., An, Y., Cao, B., Sun, R., Ke, J. and Zhao, D. (2020) The Composition of Gut Microbiota in Patients Bearing Hashimoto’s Thyroiditis with Euthyroidism and Hypothyroidism. International Journal of Endocrinology, 2020, Article ID: 5036959. [Google Scholar] [CrossRef] [PubMed]
[26] Mori, K., Nakagawa, Y. and Ozaki, H. (2012) Does the Gut Microbiota Trigger Hashimoto’s Thyroiditis? Discovery Medicine, 14, 321-326.
[27] Kiseleva, E., Mikhailopulo, K., Sviridov, O., Novik, G., Knirel, Y. and Szwajcer Dey, E. (2011) The Role of Components of Bifidobacterium and Lactobacillus in Pathogenesis and Serologic Diagnosis of Autoimmune Thyroid Diseases. Beneficial Microbes, 2, 139-154. [Google Scholar] [CrossRef] [PubMed]
[28] Kiseleva, E.P., Mikhailopulo, K.I., Novik, G.I., Szwajcer Dey, E., Zdorovenko, E.L., Shashkov, A.S., et al. (2013) Isolation and Structural Identification of Glycopolymers of Bifidobacterium Bifidum BIM B-733D as Putative Players in Pathogenesis of Autoimmune Thyroid Diseases. Beneficial Microbes, 4, 375-392. [Google Scholar] [CrossRef] [PubMed]
[29] Opazo, M.C., Ortega-Rocha, E.M., Coronado-Arrázola, I., Bonifaz, L.C., Boudin, H., Neunlist, M., et al. (2018) Intestinal Microbiota Influences Non-Intestinal Related Autoimmune Diseases. Frontiers in Microbiology, 9, Article No. 432. [Google Scholar] [CrossRef] [PubMed]
[30] 杨芸艺, 沙雯君, 雷涛, 等. 黄芪基于肠道菌群调节治疗2型糖尿病的研究进展[J]. 医学综述, 2021, 27(22): 4506-4511.
[31] 张蔚. 二氢黄酮苷及异黄酮苷与人体肠道细菌的相互作用研究[D]: [硕士学位论文]. 南京: 南京中医药大学, 2014.
[32] Feng, W., Liu, J., Tan, Y., Ao, H., Wang, J. and Peng, C. (2020) Polysaccharides from Atractylodes Macrocephala Koidz. Ameliorate Ulcerative Colitis via Extensive Modification of Gut Microbiota and Host Metabolism. Food Research International, 138, Article ID: 109777. [Google Scholar] [CrossRef] [PubMed]
[33] Chen, Z., Xu, Q., Liu, Y., Wei, Y., He, S., Lin, W., et al. (2022) Vancomycin-Induced Gut Microbiota Dysbiosis Aggravates Allergic Rhinitis in Mice by Altered Short-Chain Fatty Acids. Frontiers in Microbiology, 13, Article ID: 1002084. [Google Scholar] [CrossRef] [PubMed]
[34] 刘巧红, 赵瑜, 胡义扬. 调节肠道菌群治疗非酒精性脂肪肝的研究进展[J]. 世界中医药, 2020, 15(7): 1075-1079.
[35] 牧亚峰, 向楠, 左新河, 等. 白芍总苷对自身免疫性甲状腺炎大鼠肠黏膜屏障及肠道菌群的影响[J]. 中草药, 2021, 52(11): 3269-3277.
[36] 武静, 田维毅, 蔡坤, 等. 基于16SrRNA测序技术研究大建中汤调节肠易激综合征模型大鼠肠道菌群的作用机制[J]. 时珍国医国药, 2021, 32(8): 1814-1818.
[37] 陈籽仪. 中西医结合治疗气滞型幽门螺杆菌阳性消化性溃疡疗效观察[J]. 云南中医中药杂志, 2017, 38(2): 26-28.
[38] 花海莹, 李雪晴, 刘吉华. 生脉散对人肠道菌群失衡的调节作用[J]. 中国药科大学学报, 2016, 47(1): 95-100.
[39] Luo, S., Wen, R., Wang, Q., Zhao, Z., Nong, F., Fu, Y., et al. (2019) Rhubarb Peony Decoction Ameliorates Ulcerative Colitis in Mice by Regulating Gut Microbiota to Restoring Th17/Treg Balance. Journal of Ethnopharmacology, 231, 39-49. [Google Scholar] [CrossRef] [PubMed]
[40] 韩卓君, 吴小平, 严明煜, 等. 中药与肠道菌群相互作用机制探讨[J]. 世界中医药, 2021, 16(24): 3591-3595.
[41] Mu, Q., Kirby, J., Reilly, C.M. and Luo, X.M. (2017) Leaky Gut as a Danger Signal for Autoimmune Diseases. Frontiers in Immunology, 8, Article No. 598. [Google Scholar] [CrossRef] [PubMed]
[42] 中华医学会肠外肠内营养学分会, 中国国际医疗保健促进交流会加速康复外科分会, 中国微生态治疗创新联盟, 等. 菌群移植标准化方法学的建立与临床应用中国专家共识[J]. 中华胃肠外科杂志, 2020, 23(Z1): 5-13.
[43] 徐根兴. 益生菌的功能基因导入和基因编辑[J]. 中国生物化学与分子生物学报, 2022, 38(12): 1593-1603.